Catalyst Pharmaceuticals (CPRX) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $82.1 million.
- Catalyst Pharmaceuticals' Operating Expenses rose 557.81% to $82.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $319.4 million, marking a year-over-year increase of 1148.72%. This contributed to the annual value of $296.6 million for FY2024, which is 474.71% down from last year.
- Per Catalyst Pharmaceuticals' latest filing, its Operating Expenses stood at $82.1 million for Q3 2025, which was up 557.81% from $80.3 million recorded in Q2 2025.
- Over the past 5 years, Catalyst Pharmaceuticals' Operating Expenses peaked at $139.9 million during Q3 2023, and registered a low of $20.4 million during Q1 2021.
- In the last 5 years, Catalyst Pharmaceuticals' Operating Expenses had a median value of $52.9 million in 2023 and averaged $55.2 million.
- As far as peak fluctuations go, Catalyst Pharmaceuticals' Operating Expenses soared by 33518.14% in 2023, and later tumbled by 4438.93% in 2024.
- Catalyst Pharmaceuticals' Operating Expenses (Quarter) stood at $25.6 million in 2021, then grew by 17.17% to $30.0 million in 2022, then skyrocketed by 129.92% to $68.9 million in 2023, then increased by 14.67% to $79.0 million in 2024, then increased by 3.99% to $82.1 million in 2025.
- Its Operating Expenses was $82.1 million in Q3 2025, compared to $80.3 million in Q2 2025 and $78.1 million in Q1 2025.